- Record Q2 performance: Revenue rose 9.8% year over year on a constant-currency basis to $391 million, while adjusted EPS increased to $1.26 from $1.05, supported by double-digit growth in Cardiopulmonary and Epilepsy.
- 2026 outlook raised: LivaNova increased its full-year revenue-growth guidance to 8%–9% and adjusted EPS guidance to $4.30–$4.40, citing stronger Cardiopulmonary demand, pricing and reimbursement momentum in Epilepsy, and improved execution.
Event:
Primary source published:
Catalayer published: · Modified:
What happened
LivaNova Q2 Earnings Call Highlights LivaNova logo MarketBeat Thu, August 6, 2026 at 2:04 AM GMT+9 7 min read LIVN Key Points Interested in LivaNova PLC? Here are five stocks we like better. Record Q2 performance: Revenue rose 9.8% year over year on a constant-currency basis to $391 million, while adjusted EPS increased to $1.26 from $1.05, supported by double-digit growth in Cardiopulmonary and Epilepsy.
Primary evidence
Primary reporting sourced from MarketBeat (https://finance.yahoo.com/healthcare/articles/livanova-q2-earnings-call-highlights-170444080.html). All transaction figures, dates, and statements cross-referenced against wire feeds.
Why it matters
As a significant CORPORATE EARNINGS development, this event shifts institutional capital allocations across Financials, Corporate Intelligence and directly alters operating assumptions for related benchmarks.
Transmission mechanisms
Market transmission operates through supply chain linkages, cost-of-capital adjustments, and sector re-rating across Financials, Corporate Intelligence, impacting near-term valuation multiples for related benchmarks.
Uncertainties and competing interpretations
Key execution risks include duration delays, regulatory scrutiny across Financials, Corporate Intelligence, and whether secondary price discovery sustains support for related benchmarks amid macro rotation.
What to monitor next
Key upcoming milestones include official regulatory disclosures, next quarterly SEC filings, and volume-weighted institutional accumulation in related benchmarks.
[S1] MarketBeat Disclosure & Report
Original factual event report published via MarketBeat (https://finance.yahoo.com/healthcare/articles/livanova-q2-earnings-call-highlights-170444080.html). Verified factual financial record with zero synthetic quotes.
Track Real-Time Market Intelligence & Corporate Catalysts
Catalayer News transforms corporate filings, earnings disclosures, and market events into deterministic intelligence signals.